A Phase 1, Open-label Dose Escalation and Expansion Study Of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
This study is testing a new medication called PT0511 to see how safe and effective it is for people with advanced solid tumors. Researchers want to find the right dose of this medicine, either on its own or paired with another drug called cetuximab, to help fight cancer that has specific genetic changes.
This study is for adults over 18 who have an advanced solid tumor, such as lung, pancreatic, or colorectal cancer, that carries a specific genetic marker known as a KRAS mutation. You must have already tried other cancer treatments or be unable to take them for health reasons.
You will receive the study drug, PT0511, either alone or alongside cetuximab, while doctors closely monitor your health and any side effects. You will undergo regular check-ups and imaging scans to see how your body and your cancer respond to the treatment.
This study is currently recruiting patients at medical centers in Boston, Massachusetts, and San Antonio, Texas. It is an early-phase trial focused on determining safe dosing for future treatment.
- 1This trial tests a new drug for cancers with a specific genetic change called a KRAS mutation.
- 2Participants will receive close medical supervision to ensure the treatment is safe.
- 3You may be eligible if you have advanced cancer and have already tried other standard treatments.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.